Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
7.07
-0.20 (-2.75%)
Apr 16, 2026, 1:44 PM EDT - Market open
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 533 employees as of December 31, 2025. The number of employees increased by 165 or 44.84% compared to the previous year.
Employees
533
Change (1Y)
165
Growth (1Y)
44.84%
Revenue / Employee
$405,450
Profits / Employee
-$413,647
Market Cap
417.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 533 | 165 | 44.84% |
| Dec 31, 2024 | 368 | 165 | 81.28% |
| Dec 31, 2023 | 203 | -87 | -30.00% |
| Dec 31, 2022 | 290 | 12 | 4.32% |
| Dec 31, 2021 | 278 | -14 | -4.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sutro Biopharma | 137 |
| Enanta Pharmaceuticals | 120 |
| Aura Biosciences | 113 |
| Century Therapeutics | 78 |
| Armata Pharmaceuticals | 60 |
| Altimmune | 57 |
| PureTech Health | 56 |
| Eupraxia Pharmaceuticals | 49 |
VNDA News
- 7 days ago - Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - PRNewsWire
- 7 days ago - Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PRNewsWire
- 27 days ago - Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - PRNewsWire
- 6 weeks ago - Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - PRNewsWire
- 6 weeks ago - Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - PRNewsWire
- 7 weeks ago - Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Benzinga
- 7 weeks ago - Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 7 weeks ago - Vanda Pharmaceuticals stock's explosive rally may be more hype than substance - Invezz